# Prevention of Lymphorrhea by Lanreotide in Axillary Dissection for Breast Cancer

> **NCT00630695** · PHASE3 · COMPLETED · sponsor: **University Hospital, Limoges** · enrollment: 148 (actual)

## Conditions studied

- Lymphocele

## Interventions

- **DRUG:** Lanreotide LP 90
- **DRUG:** Placebo lanreotide

## Key facts

- **NCT ID:** NCT00630695
- **Lead sponsor:** University Hospital, Limoges
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2011-06
- **Final completion:** 2011-12
- **Target enrollment:** 148 (ACTUAL)
- **Last updated:** 2012-01-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00630695

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00630695, "Prevention of Lymphorrhea by Lanreotide in Axillary Dissection for Breast Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00630695. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*